The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies. We will deploy our first fund of approximately $260M to build 8-10 disease-focused drug discovery companies, each with the potential to become a leader in their respective field(s). These companies will be strongly supported by the unique and complementary skill-sets of our team, which includes prominent authorities in the scientific, operational and financial arenas. Typically, we will commit $20M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group seeks to partner with exceptional scientific founders, entrepreneurs, executives and investment organizations that share our vision for building the next generation of drug discovery and development companies.